Statement: the primary trial participants recieve doses of Pralatrexate that are calculated based on bodyweight. cdkn2a protein variant is a variation in the amino acid sequence for a protein encoded by the cdkn2a gene.
Primary_evidence: INTERVENTION 1:    Pralatrexate   Study drug 190 mg/m^2 for 2 to 4 weeks.